Navigation Links
IDM Pharma Reports 2008 Financial Results
Date:3/31/2009

ion in the prior year period. SG&A expenses decreased to $10.1 million for the year ended December 31, 2008 from $12.6 million for the year ended December 31, 2007. The higher expenses for the full year 2007 included $0.5 million in fees to an investment advisor in relation to the $12.9 million private equity financing completed in February 2007, $0.8 million associated with cash severance benefits for our former chief executive officer and $0.9 million in higher spending for finance-related consultants, offset by $0.3 million in accrued restoration costs for our Irvine, California facility. Expenses for the 2008 period were also lower due to $0.5 million in savings from the closing of our Paris, France office.

Restructuring expenses were $3.5 million for the year ended December 31, 2008, which was for the closing of our Paris, France office following notification of sanofi-aventis' decision in December 2007 to terminate its participation in the UVIDEM development program. The $3.5 million includes $3.2 million of severance benefits and $0.6 million of shutdown costs, offset by $0.3 million of proceeds from the sale of fixed assets.

Interest income decreased to $0.1 million for the three months ended December 31, 2008 from $0.4 million in the prior year period. Interest income decreased to $0.7 million for the year ended December 31, 2008 from $1.1 million in 2007. Higher interest income in 2007 was primarily the result of higher cash investment balances due to the February and June 2007 financings.

Interest expense related to warrants for the quarter ended December 31, 2008 was a negative expense of $1.6 million compared with a negative expense of $1.1 million in the quarter ended December 31, 2007. Interest expense for the year ended December 31, 2008 was $3.1 million compared to a negative expense of $3.9 million for the year ended December 31, 2007. The interest expense in both the quarter and
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors
2. The MedZilla Report: Febraury 2009 Employment Outlook for Biotech/Pharma/Health
3. Recent Graduates Finding BioTech & Pharmaceutical Jobs Easier Than Ever With The Launch of CampusRXBio
4. VIA Pharmaceuticals Complies With NASDAQ Rules
5. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results
6. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
8. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
9. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
10. Isis Pharmaceuticals to Present at the 4th Annual Citi Biotech Day
11. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015 VG Life ... therapies for autoimmune and infectious diseases, announced that ... issued an important new composition of matter patent ... the targeting of CLIP. U.S. ... underlying VG Life Sciences, VG1177, a synthetic peptide ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 ... newly formed alliance with Shenzhen HANK Bioengineering Co., ... Ph.D. The alliance will establish a stem cells ... Province, China in September 2015. , Shenzhen HANK ... Zhang, an award-winning scientist, microbiologist and virologist, to ...
(Date:3/1/2015)... 2015 Market Publishers Ltd and ... market research promotion on Internet. MarketPublishers.com is now ... out by DataGroup Booksellers. , Natalie Aster, Assistant ... commented on the recent partnership agreement as follows: ... our team of publishers. Since 1974, the company ...
(Date:2/27/2015)... Immunovaccine Inc. (“Immunovaccine” or the “Company”) (TSX: ... release disseminated this morning by PR Web, and redistributed ... release states that Immunovaccine has entered into a co-development ... did not originate from Immunovaccine and there is no ... Please note that all official statements by Immunovaccine ...
Breaking Biology Technology:VG Life Sciences Granted Key Composition Of Matter Patent 2VG Life Sciences Granted Key Composition Of Matter Patent 3Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 3Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 2Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 3Immunovaccine Disclaims Hoax Press Release 2
... of Pennsylvania research team have shown that they can prevent, ... or XLRP, in dogs. The disease in humans and ... results in early, severe and progressive vision loss. It is ... in man. "Every single abnormal feature that defines ...
... University of New South Wales have observed a new kind ... silicon transistor. The findings, to be published this week ... more complete understanding of the mechanisms for electron transport in ... able to study some of the most complicated transport mechanisms ...
... N.Y. Graphene is the thinnest material known to science. ... even know it,s there. Engineering researchers at Rensselaer Polytechnic ... silicon with a single layer of graphene, and then placed ... layer of graphene proved to have virtually no impact on ...
Cached Biology Technology:Gene therapy research from Penn Vet & Scheie Eye Inst. cures retinitis pigmentosa in dogs 2Gene therapy research from Penn Vet & Scheie Eye Inst. cures retinitis pigmentosa in dogs 3A new class of electron interactions in quantum systems 2Nature Materials study: Graphene 'invisible' to water 2Nature Materials study: Graphene 'invisible' to water 3Nature Materials study: Graphene 'invisible' to water 4
(Date:2/13/2015)... 13, 2015 ACT Genomics Co., Ltd., ... to transform cancer genomic information into precision diagnosis ... has raised US$ 8 million in the its first ... Taipei, Taiwan , ACT Genomics has ... the aim to implement next generation sequencing (NGS) ...
(Date:2/10/2015)... -- Alere Inc. (NYSE: ALR), a global leader in ... quarter ended December 31, 2014. Namal ... said, "We made substantial progress in the fourth ... in rapid diagnostics and delivering against our financial ... early January enabled us to substantially reduce our ...
(Date:2/5/2015)...   Epic Sciences , a precision diagnostics company dedicated ... Murali Prahalad , Ph.D., president and CEO, is scheduled to ... 2015: Silicon Valley, which is taking place at the Computer ... on January 26-28, 2015. Dr. Prahalad will ... Last year, Epic Sciences was a finalist in the PMWC,s ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35
... mammals haven,t always been what they are today, particularly for ... lions and tigers and other big cats as examples. ... plant-eaters, living on a diet of leaves, shoots, fruits and ... foods in addition to meat, the situation wasn,t always that ...
... of researchers at the Institute for Research in Biomedicine (IRB ... the first time to extract trustworthy structural information from a ... in conditions in which DNA is practically in a vacuum. ... American Chemical Society (JACS), one of the journals with ...
... results presented at 3rd European Lung Cancer Conference in ... the diagnosis and treatment of malignant pleural mesothelioma, an ... caused by asbestos exposure. Micro RNAs speed ... molecule that is more abundant in the blood of ...
Cached Biology News:Scientists trace evolutionary history of what mammals eat 2First description of a triple DNA helix in a vacuum 2Promising developments in early diagnosis and treatment of mesothelioma 2Promising developments in early diagnosis and treatment of mesothelioma 3Promising developments in early diagnosis and treatment of mesothelioma 4